Has NEU applied to FDA for IND in relation to the new indications. They have had enough time to submit the animal studies and other preclinical data to the FDA.
It would certainly be exciting to have these indications released with FDA approvals to go into a PH2 trials .
From memory the first 4 indications came with the FDA IND announcement and start of ph1 trials.
Think the first Ph1 trials should cover off the safety and toxicity profile of 2591.
- Forums
- ASX - By Stock
- NEU
- NEU is materially undervalued
NEU
neuren pharmaceuticals limited
Add to My Watchlist
6.14%
!
$13.31

NEU is materially undervalued, page-146
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.31 |
Change
0.770(6.14%) |
Mkt cap ! $1.655B |
Open | High | Low | Value | Volume |
$12.96 | $14.00 | $12.91 | $19.76M | 1.453M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3000 | $13.30 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.33 | 3716 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3000 | 13.300 |
2 | 10200 | 13.200 |
1 | 2500 | 13.190 |
2 | 1750 | 13.180 |
1 | 50 | 13.170 |
Price($) | Vol. | No. |
---|---|---|
13.330 | 3716 | 1 |
13.370 | 3716 | 1 |
13.390 | 600 | 1 |
13.400 | 3783 | 2 |
13.430 | 3716 | 1 |
Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
3DA
AMAERO LTD
Hank Holland, Chairman & CEO
Hank Holland
Chairman & CEO
Previous Video
Next Video
SPONSORED BY The Market Online